MarketInOut Stock Screener Log In | Sign Up
 

Entera Bio Ltd

NASDAQ • Healthcare • Biotechnology • Quote as of 07/24/2026
Entera Bio Ltd stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization100.06 mln
Float40.37 mln
Earnings Date08/07/2026

Piotroski F-Score

2 / 9
Weak

Relative Strength

99 / 100
Top performer

Debt / Equity

0.04
Debt-free

ROE

-81.80
Deeply negative

Dividend Yield

0.00%
No dividend

DPS

0.00
No dividend

Business Description

Entera Bio is an Israel-based company focused on turning injectable hormone and protein treatments into pills that patients can swallow. The company has several drugs in clinical testing, targeting conditions such as osteoporosis, obesity, and rare hormonal disorders. Its most advanced candidate is an oral version of teriparatide, a drug commonly used to treat bone loss, which has already completed a mid-stage clinical trial. Entera also works with partner companies to advance additional treatments through early-stage research and testing.

Key Fundamentals

EPS-0.26
ROE-81.80
ROIC-160
ROA-70.49
EBITDA, mln-12.48
EV / EBITDA-6.14
EV / EBIT-6.13
EV / Revenue1,825

Financial Strength

Piotroski F-Score 2 / 9
Short Ratio0.12
Short % of Float0.78

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 3.54% 90 / 100   
1 Month 33.12% 98 / 100   
2 Months 70.83% 98 / 100   
6 Months 29.75% 90 / 100   
1 Year 6.22% 52 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us